3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Non-Hodgkin
3
Recurrence
2
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Hodgkin Disease
2
Various Advanced Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Gastroesophageal Cancer
1
Fallopian Tube Neoplasms
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Advanced Cancer
1
Interventions
relatlimab
1
daratumumab
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Various Advanced Cancer
×
relatlimab
×
Clear all
NCT02488759
2023-11-13
CheckMate358
Bristol-Myers Squibb
Phase 1/2
Completed
578 enrolled
19 charts